Article snapshot taken from Wikipedia with creative commons attribution-sharealike license.
Give it a read and then ask your questions in the chat.
We can research this topic together.
Decoy receptor 3 (Dcr3), also known as tumor necrosis factor receptor superfamily member 6B (TNFRSF6B), TR6 and M68, is a soluble protein of the tumor necrosis factor receptor superfamily which inhibits Fas ligand-induced apoptosis.
Discovery
Dcr3 was identified in 1998 by the search of genes with homology to the TNFR gene superfamily in expressed sequence tag (EST) database.
Structure
The open reading frame of TNFRSF6B encodes 300 amino acids with a 29-residue signal sequence and four tandem cystein-rich repeats. Two transcript variants encoding the same isoform, but differing in the 5' UTR, have been observed for this gene. Unlike most of the other members of TNFR superfamily, TNFRSF6 is a soluble protein which contains no transmembrane domain.
Function
This gene belongs to the tumor necrosis factor receptor superfamily. It acts as a decoy receptor that competes with death receptors for ligand binding. The encoded protein is postulated to play a regulatory role in suppressing FasL- and LIGHT-mediated cell death and T cell activation as well as to induce angiogenesis via neutralization of TL1A. Overexpression of this gene has been noted in various tumors e.g. gastrointestinal tract tumors, and it is located in a gene-rich cluster on chromosome 20, with other potentially tumor-related genes.
"Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
^ Pitti RM, Marsters SA, Lawrence DA, Roy M, Kischkel FC, Dowd P, Huang A, Donahue CJ, Sherwood SW, Baldwin DT, Godowski PJ, Wood WI, Gurney AL, Hillan KJ, Cohen RL, Goddard AD, Botstein D, Ashkenazi A (Jan 1999). "Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer". Nature. 396 (6712): 699–703. doi:10.1038/25387. PMID9872321. S2CID4427455.
Mild G, Bachmann F, Boulay JL, et al. (2002). "DCR3 locus is a predictive marker for 5-fluorouracil-based adjuvant chemotherapy in colorectal cancer". Int. J. Cancer. 102 (3): 254–7. doi:10.1002/ijc.10711. PMID12397645. S2CID23680078.